MarketCap
Prelude Therapeutics Incorporated PRLD
$ 3.8
0.53%
Facebook
X
Telegram
Prelude Therapeutics Incorporated Total Liabilities | PRLD
Annual Total Liabilities Prelude Therapeutics Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 72.7 M | 44.1 M | 40.6 M | 25.1 M | 19.2 M | 11.4 M | 71.3 M | 39.1 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 72.7 M | 11.4 M | 40.4 M |
Quarterly Total Liabilities Prelude Therapeutics Incorporated
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 72.7 M | 59.5 M | 44.1 M | 36.2 M | 39.1 M | 38.1 M | 40.6 M | 40.8 M | 42 M | 36.4 M | 25.1 M | 20.3 M | 18.6 M | 23 M | - | 24.9 M | 18.2 M | 18.9 M | 19.2 M | 20 M | 15.2 M | 13.3 M | 11.4 M | 11.4 M | 11.4 M | 11.4 M | 4.84 M | 4.84 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 72.7 M | 4.84 M | 26.7 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
46.8 M | - | - | $ 24.9 M |  USA |
 |
Brickell Biotech
BBI
|
4.81 M | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
29.7 M | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
3.51 M | - | - | $ 8.86 M |  Canada |
 |
Generation Bio Co.
GBIO
|
145 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
64 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
135 M | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
50.4 M | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
65.9 M | $ 4.2 | -0.36 % | $ 651 M | USA |
 |
AbbVie
ABBV
|
97.3 B | $ 294.72 | 0.32 % | $ 521 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
8.23 M | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Avenue Therapeutics
ATXI
|
1.1 M | - | -52.27 % | $ 4.45 M | USA |
 |
Achieve Life Sciences
ACHV
|
20.3 M | $ 6.78 | 0.89 % | $ 296 M | USA |
 |
Axon Enterprise
AXON
|
3.76 B | $ 316.97 | 4.77 % | $ 24.7 B | USA |
 |
TFF Pharmaceuticals
TFFP
|
2.46 M | - | -60.05 % | $ 125 K | USA |
 |
Bristol-Myers Squibb Company
BMY
|
71.5 B | $ 62.89 | 0.18 % | $ 128 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
234 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Axcella Health
AXLA
|
14.8 M | - | -16.42 % | $ 249 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
2.08 B | $ 58.59 | 4.29 % | $ 7.04 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
389 M | - | - | $ 2.02 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
4.18 B | $ 159.75 | 5.35 % | $ 20.9 B | USA |
 |
Amgen
AMGN
|
50 B | $ 467.97 | 0.59 % | $ 252 B | USA |
 |
Orgenesis
ORGS
|
38.9 M | - | -33.86 % | $ 61.2 M | USA |
 |
Codiak BioSciences
CDAK
|
118 M | - | -55.98 % | $ 2.15 M | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
2.43 B | $ 248.31 | 1.17 % | $ 15.1 B |  Irlanda |
 |
Johnson & Johnson
JNJ
|
118 B | $ 280.31 | -0.17 % | $ 675 B | USA |
 |
Kala Pharmaceuticals
KALA
|
2.49 M | $ 0.17 | 0.64 % | $ 1.39 M | USA |
 |
BioLineRx Ltd.
BLRX
|
17.6 M | $ 1.49 | -1.97 % | $ 3.67 B | Israel |
 |
Sage Therapeutics
SAGE
|
82.1 M | - | - | $ 527 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 1.59 | -2.76 % | $ 2.62 M | Israel |
 |
Lineage Cell Therapeutics
LCTX
|
69.2 M | $ 1.13 | 8.17 % | $ 260 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
344 M | - | - | $ 121 M | USA |
 |
TCR2 Therapeutics
TCRR
|
67.4 M | - | - | $ 58.1 M | USA |
 |
C4 Therapeutics
CCCC
|
102 M | $ 2.9 | -3.5 % | $ 240 M | USA |
 |
Eli Lilly and Company
LLY
|
36.6 B | $ 1 437.4 | 0.36 % | $ 1.29 T | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
37.9 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Compugen Ltd.
CGEN
|
18.5 M | $ 2.09 | -0.24 % | $ 195 M | Israel |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
134 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
GeoVax Labs
GOVX
|
2.52 M | $ 2.13 | -20.4 % | $ 2.04 M | USA |
 |
Unity Biotechnology
UBX
|
31.2 M | - | -33.41 % | $ 3.37 M | USA |
 |
MediciNova
MNOV
|
4.02 M | $ 1.41 | 0.36 % | $ 69.2 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
59.5 M | - | - | $ 521 M | USA |
 |
Seelos Therapeutics
SEEL
|
38.9 M | - | -47.76 % | $ 6.27 M | USA |
 |
Celldex Therapeutics
CLDX
|
55.8 M | $ 30.18 | -1.53 % | $ 2 B | USA |
 |
Moderna
MRNA
|
3.69 B | $ 248.62 | -0.88 % | $ 96.7 B | USA |